The Effect of Instability of Baseline Severity of Positive Symptoms on End of Treatment Change in the PANSS Negative Factor Score in Negative Symptom Schizophrenia Studies - An Exploratory Post-Hoc Analysis

被引：0
|
作者：
Daniel, David [1 ]
Wang, Xingmei [1 ]
Kott, Alan [1 ]
机构：
[1] Signant Hlth, Mclean, VA USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2021年 / 46卷 / SUPPL 1期
关键词：
CNS Clinical Trials; Negative Symptoms; Positive Symptoms; Schizophrenia;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P554
引用
收藏
页码：371 / 371
页数：1
相关论文
共 22 条
  • [1] A POST-HOC ANALYSIS OF THE NEGATIVE SYMPTOM FACTOR SCORE IN A PROOF-OF-CONCEPT WITH A GLYCINE REUPTAKE INHIBITOR (GRI) IN SCHIZOPHRENIA
    Umbricht, Daniel
    Lentz, Ellen L.
    Santarelli, Luca
    Lalonde, Justine
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S360 - S360
  • [2] A post-hoc analysis of the negative symptom factor score in a proof-of-concept study of glycine reuptake inhibitor bitopertin in schizophrenia
    Umbricht, D.
    Lentz, E.
    Santarelli, L.
    Lalonde, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S311 - S311
  • [3] Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms
    Edgar, Chris J.
    Blaettler, Thomas
    Bugarski-Kirola, Dragana
    Le Scouiller, Stephanie
    Garibaldi, George M.
    Marder, Stephen R.
    PSYCHIATRY RESEARCH, 2014, 218 (1-2) : 219 - 224
  • [4] What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
    Czobor, Pal
    Sebe, Barbara
    Acsai, Karoly
    Barabassy, Agota
    Laszlovszky, Istvan
    Nemeth, Gyoergy
    Furukawa, Toshi A.
    Leucht, Stefan
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [5] EFFICACY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA WITH PROMINENT NEGATIVE SYMPTOMS: A POST-HOC ANALYSIS OF SHORT-TERM TRIALS
    Pikalov, Andrei
    Schooler, Nina
    Hsu, Jay
    Cucchiaro, Josephine
    Goldman, Robert
    Loebel, Antony
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S355 - S355
  • [6] Efficacy of Lurasidone in the Treatment of Schizophrenia with Prominent Negative Symptoms: A Post-hoc Analysis of Short-term Trials
    Schooler, Nina R.
    Pikalov, Andrei
    Hsu, Jay
    Cucchiaro, Josephine
    Goldman, Robert
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S513 - S514
  • [7] Efficacy of lurasidone in the treatment of schizophrenia with prominent negative symptoms: A post-hoc analysis of short-term trials
    Schooler, N. R.
    Pikalov, A.
    Hsu, J.
    Cucchiaro, J.
    Goldman, R.
    Loebel, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 151 - 152
  • [8] Efficacy of lurasidone in the treatment of schizophrenia with prominent negative symptoms: a post-hoc analysis of five short-term trials
    Schooler, N. R.
    Pikalov, A.
    Hsu, J.
    Cucchiaro, J.
    Goldman, R.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S558 - S558
  • [9] The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
    Laszlovszky, I.
    Dombi, Z. B.
    Balogh, A.
    Barabassy, A.
    Vass, G.
    Szatmari, B.
    Nemeth, G.
    EUROPEAN PSYCHIATRY, 2021, 64 : S533 - S533
  • [10] Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition
    Marder, S.
    Laszlovszky, I.
    Szalai, E.
    Szatmari, B.
    Harsanyi, J.
    Barabassy, A.
    Debelle, M.
    Durgam, S.
    Bitter, I.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S550 - S550
123